Keisuke Aoe
Okayama University
CancerInternal medicineSurgeryPathologyOncologyRespiratory diseaseLung cancerChemotherapyMesotheliomaLungCisplatinEpidermal growth factor receptorPleural effusionNivolumabGefitinibPleural mesotheliomaPhases of clinical researchCancer researchMedicineBiologyGastroenterology
Publications 182
#1Kazuhiko Nakagawa (Kindai University)H-Index: 98
#2Takashi Kijima (Hyogo College of Medicine)H-Index: 24
Last. Masayuki Takeda (Kindai University)H-Index: 30
view all 19 authors...
Abstract Introduction YS110, a humanized monoclonal antibody with high affinity to CD26, showed promising antitumor activity and was generally well tolerated in the phase I part of a phase I/II Japanese trial in patients with malignant pleural mesothelioma (MPM). Here we report results of the phase II part of the study. Methods Patients were aged ≥20 years, had histologically confirmed MPM, were refractory to or intolerant of existing antineoplastic agents, and were not candidates for standard t...
#1Naoko Sueoka-Aragane (Saga University)H-Index: 13
#2Chiho Nakashima (Saga University)H-Index: 5
Last. Atsushi Kawaguchi (Saga University)H-Index: 25
view all 27 authors...
Background EGFR mutations are good predictive markers of efficacy of EGFR tyrosine kinase inhibitors (EGFR-TKI), but whether comprehensive genomic analysis beyond EGFR itself with circulating tumor DNA (ctDNA) adds further predictive or prognostic value has not been clarified. Methods Patients with NSCLC who progressed after treatment with EGFR-TKI, and with EGFR T790 M detected by an approved companion diagnostic test (cobas® ), were treated with osimertinib. Plasma samples were collected befor...
#1Nobukazu FujimotoH-Index: 22
#2Morihito Okada (Hiroshima University)H-Index: 58
Last. Jun HiranoH-Index: 1
view all 11 authors...
Abstract Introduction We examined the long-term efficacy and safety of nivolumab, a human monoclonal antibody that inhibits interactions between the programmed cell death protein-1 receptor and its ligands (programmed death-ligand 1 and programmed death-ligand 2), in Japanese patients with malignant pleural mesothelioma (MPM). Methods Japanese patients with previously treated MPM (one or two regimens) were enrolled in a single-arm, phase 2 study and received nivolumab intravenously 240 mg every ...
#1Shigeru Tanzawa (Teikyo University)H-Index: 3
#2Sunao UshijimaH-Index: 5
Last. Nobuhiko Seki (Teikyo University)H-Index: 17
view all 44 authors...
Background:Based on the results of the PACIFIC study, chemoradiotherapy followed by 1-year consolidation therapy with durvalumab was established as the standard of care for unresectable, locally ad...
#1Takashi SetoH-Index: 51
#2Kadoaki Ohashi (Okayama University)H-Index: 19
Last. Toyoaki HidaH-Index: 65
view all 10 authors...
MET mutations leading to exon 14 skipping (METΔex14) are strong molecular drivers for non-small-cell lung cancer (NSCLC). Capmatinib is a highly potent, selective oral MET inhibitor that showed clinically meaningful efficacy and a manageable safety profile in a global Phase II study (GEOMETRY mono-1, NCT02414139) in patients with advanced METΔex14-mutated/MET-amplified NSCLC. We report results of preplanned analyses of 45 Japanese patients according to MET status (METΔex14-mutated or MET-amplifi...
#1Kadoaki Ohashi (Okayama University)H-Index: 19
#2Kiichiro Ninomiya (Okayama University)H-Index: 10
Last. Katsuyuki Kiura (Okayama University)H-Index: 67
view all 21 authors...
Abstract Objectives Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are standard treatment for EGFR-mutated non-small-cell lung carcinoma (NSCLC); however, a biomarker to predict their efficacy has not been established. Although human epidermal growth factor receptor-2 (HER2) aberrations constitute a potential mechanism for acquired resistance to EGFR-TKIs, the impact of HER2 on EGFR-TKI treatment outcomes has not been systematically evaluated. In this post-hoc subgroup...
#1Miyako SatouchiH-Index: 37
#2Kaname NosakiH-Index: 15
Last. Katsuyuki Hotta (Okayama University)H-Index: 37
view all 26 authors...
This prespecified subanalysis of the global, randomized controlled phase III KEYNOTE-024 study of pembrolizumab vs chemotherapy in previously untreated metastatic non-small-cell lung cancer without EGFR/ALK alterations and a programmed death ligand 1 (PD-L1) tumor proportion score of 50% or higher evaluated clinical outcomes among patients enrolled in Japan. Treatment consisted of pembrolizumab 200 mg every 3 weeks (35 cycles) or platinum-based chemotherapy (four to six cycles). The primary end-...
1 CitationsSource
#2Yuka Mimura-KimuraH-Index: 6
Last. Yusuke MimuraH-Index: 14
view all 9 authors...
Background: Acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF) are episodes of acute respiratory worsening characterized by diffuse alveolar damage superimposed on usual interstitial pneumonia. Direct hemoperfusion with a polymyxin B-immobilized fiber column (PMX-DHP) is reported to have beneficial effects on the respiratory status and outcome in patients with AE-IPF although its mechanism of action is not fully elucidated. Objective: To investigate whether and how the PMX-immobilized...
#1Nobukazu FujimotoH-Index: 22
#2Toshiyuki KozukiH-Index: 22
Last. K. HottaH-Index: 1
view all 9 authors...
#1Hidetoshi HayashiH-Index: 29
#2Morihito OkadaH-Index: 58
Last. Yuichiro OheH-Index: 72
view all 13 authors...
1 CitationsSource